Simultaneous determination of endogenous deoxynucleotides and phosphorylated nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cells using ion-pair liquid chromatography coupled to mass spectrometry

Proteomics - Clinical Applications

Volumn 2, Issue 10-11, 2008, Pages 1557-1562

  Coulier, Leon ^a   van Kampen, Jeroen J A ^b,c   de Groot, Ronald ^d   Gerritsen, Henk W ^a   Bas, Richard C ^a   van Dongen, William D ^a   Brüll, Lars P ^a   Luider, Theo M ^c  

^a TNO   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

HIV; Intracellular; Ion pair; Nucleoside reverse transcriptase inhibitor; Nucleotide

Indexed keywords

ABACAVIR; CARBOVIR; DEOXYRIBONUCLEOSIDE TRIPHOSPHATE; DEOXYRIBONUCLEOTIDE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANALYTIC METHOD; ARTICLE; CELL LEVEL; CELL LYSATE; CONTROLLED STUDY; DRUG CELL LEVEL; HUMAN; HUMAN CELL; ION PAIR CHROMATOGRAPHY; ISOLATION PROCEDURE; PERFORMANCE MEASUREMENT SYSTEM; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUADRUPOLE MASS SPECTROMETRY; SEPARATION TECHNIQUE;

EID: 67449167564     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200800002     Document Type: Article

References (16)

1. Hennessy, M., Clarke, S., Spiers, J. P., Mulcahy, F. et al., Intracellular indinavir pharmacokinetics in HIV-infected patients: Comparison with plasma pharmacokinetics. Antivir. Ther. 2003, 8, 191-198.
2. Djabarouti, S., Breilh, D., Pellegrin, I., Lavit, M. et al., Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study). J. Antimicrob. Chemother. 2006, 58, 1090-1093.
3. Back, D. J., Burger, D. M., Flexner, C. W., Gerber, J. G., The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: Implications for once-daily dosing. J. Acquir. Immune Defic. Syndr. 2005, 39, S1-S23, quiz S24-S25.
4. Gao, W. Y., Shirasaka, T., Johns, D. G., Broder, S., Mitsuya, H., Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Invest. 1993, 91, 2326-2333.
5. Lewis, W., Day, B. J., Copeland, W. C., Mitochondrial toxicity of NRTI antiviral drugs: An integrated cellular perspective. Nat. Rev. Drug. Discov. 2003, 2, 812-822.
6. Hoggard, P., Khoo, S., Barry, M., Back, D., Intracellular metabolism of zidovudine and stavudine in combination. J. Infect. Dis. 1996, 174, 671-672.
7. Compain, S., Schlemmer, D., Levi, M., Pruvost, A. et al., Development and validation of a liquid chromatographic/tandem mass spectrometric assay for the quantitation of nucleoside HIV reverse transcriptase inhibitors in biological matrices. J. Mass Spectrom. 2005, 40, 9-18.
8. Allinquant, B., Musenger, C., Schuller, E., Reversed-phase high-performance liquid chromatography of nucleotides and olignucleotides. J. Chromatogr. 1985, 326, 281-291.
9. Federn, H., Ristow, H., Isolation of standard-, deoxy- and highly phosphorylated nucleotides fromBacillus brevis and their separation by ion-pair high-performance liquid chromatography. Chromatographia 1986, 22, 287-291.
10. Lopez, S. L. B., Moal, J., Serrano, F. S. J., Development of a method for the analysis of nucleotides from the mantle tissue of the mussel Mytilus galloprovincialis. J. Chromatogr. A 2000, 891, 99-107.
11. Uesugi, T., Sano, K., Uesawa, Y., Ikegami, Y., Mohri, K., Ion-pair reversed-phase high-performance liquid chromatography of adenine nucleotides and nucleoside using triethylamine as a counterion. J. Chromatogr. B 1997, 703, 63-74.
12. Coulier, L., Bas, R., Jespersen, S., Verheij, E. et al., Simultaneous quantitative analysis of metabolites using ion-pair liquid chromatography-electrospray ionization mass spectrometry. Anal. Chem. 2006, 78, 6573-6582.
13. Anderson, P. L., Kakuda, T. N., Kawle, S., Fletcher, C. V., Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003, 17, 2159-2168.
14. Becher, F., Landman, R., Mboup, S., Kane, C. N. et al., Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients. AIDS 2004, 18, 181-187.
15. Hawkins, T., Veikley, W., St Claire, R. L., III, Guyer, B. et al., Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. 2005, 39, 406-411.
16. Yuen, G. J., Lou, Y., Bumgarner, N. F., Bishop, J. P. et al., Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob. Agents Chemother. 2004, 48, 176-182.